Barriers Eased, U.S. Ramps Up Drug-Plant Inspection Staff In China
This article was originally published in PharmAsia News
Having ramped up its drug-plant inspection operations in India, U.S. FDA has turned its focus on China where it is increasing local staff, including inspectors, after experiencing several delays.
You may also be interested in...
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.